linked CD70 to immunosuppression and augmented anti-tumor responses by engineering IL-8 receptor (CXCR1/CXCR2)-modified anti-CD70 CAR-T, leveraging radiation-induced IL-8 release to enhance tumor trafficking (45). Here, CXCR2 is linked to neoplasm.